NewBiologix’s Post

In case you missed it: In this session, Jean-Marc Guedon of Culture Biosciences discussed the power of Design of Experiments (DoE) in optimizing CHO cell culture for upstream bioprocessing. Register for this on-demand webinar to learn: -How DoE enables exploration of the design space and sets the foundation for a robust and scalable upstream process -How MilliporeSigma optimized their CHOZN® cell line, media and feeding regimens - How Culture Biosciences serves as an extension of your team to debottleneck process development #processdevelopment #processoptimization #mAbs #CHO #bioprocess https://lnkd.in/eBiBEtkn

Just Published: Case Study: Controlling the Wound Environment ======= Influencing the wound environment plays a pivotal role on wound responses, dressings and advanced therapies, time to heal, and ultimately, the healed outcome. Highlighted within this article are the special capabilities of a product using XBIO™ technology, and the significance of biofilm focused wound care. ---- PDF: https://lnkd.in/gbHKU3Zx #XBIO™ #biofilm #woundcare

Interested in learning more about organoids? Join our webinar with our Field Application Scientist Idil Arioz for comprehensive insights in this field.

Ramping up on the conference circuit...I'll be presenting some of the latest from Manifold Bio at the MassBio 2024 Align Summit on Thursday (April 25) at 11:15am. The conference theme is AI/ML methods in biotech, and I suspect we'll hear a lot about the importance of generating the right data. To make drugs, the right data is in vivo data, measurements of drug candidates navigating actual living systems. At Manifold, we have a unique and critical edge on this point: we've solved high-throughput in vivo data generation. This uniquely empowers our ability to design medicines that get to the right tissues. We're using this superpower to build a pipeline of brain-shuttled biologics. Excited to share more! https://lnkd.in/e_3chz4J #AlignSummit24 #AlignSummit #AIDrugDiscovery  

🧬 At Sibylla, we're thrilled to unveil a turning point for the biotech sector! Our groundbreaking cotranslational protein folding simulation platform is live. 👩🔬 Thanks to our proprietary computational platform, we can predict the folding pathways of proteins while they are synthesized by the ribosome. This means we can characterize long-lived metastable states appearing during the folding process and hosting druggable pockets hidden in the native state. 🚀 Implications? Huge. 💊 This enables us to explore the folding intermediate states as a new class of therapeutic targets. Our disrupting PPI-FIT (Pharmacological Protein Inactivation by Folding Intermediate Targeting) technology can be applied to undruggable proteins to find new therapeutics for untreatable diseases. 💡 We're just getting started. Stay tuned for more updates, and follow us while we #foldthefuture. #BiotechInnovation #ProteinFolding #DrugDiscovery #Sibylla --- 🔗 Learn more at www.sibyllabiotech.it ---

Precision, versatility and efficiency are key to the success of CRISPR screening. In this sense, Vivlion's 3Cs technology for CRISPR library generation represents a revolutionary shift in the approach to drug discovery. By choosing Vivlion for your screening services, you will not only benefit from the use of uniform and target-optimized libraries, but also from working with a skilled team of scientists who will help you take your target discovery pipeline to new heights. We are your strategic screening partner, guiding you from project design to experimental execution and data analysis. Switch to 3Cs technology - where precision meets efficiency and breakthrough discoveries await. Reach out to us if you want to learn more. #drugdiscovery #crispr #biotechnology

How to build an #AAVplatform that produces higher titers and percent full #capsids Next month, join Leisha Kopp (Senior Field Applications Scientist, Mirus Bio) and Chris Brown (Senior Scientist of Process Development, ReciBioPharm) as they explore a #transfectionreagent and enhancer platform that increases both #AAVtiters and percent full capsids by 2- to 10-fold over existing technologies, regardless of #serotype, media choice, or suspension #HEKcell type. Attend to learn about: • Increasing both AAV titers and percent full capsids by 2- to 10-fold over existing technologies, regardless of serotype, media choice, or suspension HEK cell type • Case study data highlighting how a novel platform achieves high titers and percent full capsids without sacrificing efficiency • How to reduce cost per bioreactor run, and ultimately drive down cost per patient dose Register for this upcoming #webinar below:

Ever wonder how Nuvolos performs on a complex biotech pipeline? Using Cellranger Multi, we show you how easy, flexible, and performant it is. https://lnkd.in/eDru3ah2

Ever wonder how Nuvolos performs on a complex biotech pipeline? Using Cellranger Multi, we show you how easy, flexible, and performant it is. https://lnkd.in/eDru3ah2

Be sure to connect with Amanda Limongi at ADLM to learn more about Vexillum Biobank!